| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2883573 | The Annals of Thoracic Surgery | 2006 | 7 Pages |
Abstract
The C5 complement inhibitor, pexelizumab, reduced morbidity and mortality among high-risk patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Axel MD, Stanton K. MD, Jerrold H. MD, John C. MD, Michel MD, Kenneth M. MD, Frans MD, PhD, Mark F. MD, Peter X. MD, Thomas G. MD, JD, Michael MD, Edward D. MD,